ARCHIVED: NOT AVAILABLE FOR CREDIT
Continuous Evolution: Current and Emerging Indications for Molecular Pathology in Lung Cancer

Lecture Presenter

Neal I. Lindeman, MD Vice Chair, Molecular Pathology Brigham and Women's Hospital Associate Professor of Pathology Director, Molecular Genetic Pathology Fellowship Program Harvard Medical School

Neal Lindeman, MD, is vice chair for Molecular Pathology at the Brigham and Women's Hospital, and associate professor of Pathology at Harvard Medical School. Dr. Lindeman is certified by the American Board of Pathology (Anatomic and Clinical Pathology, 1999; Molecular Genetic Pathology, 2001) and the American Board of Clinical Chemistry (Molecular Diagnostics, 2000), and has been practicing molecular pathology since 1999, serving as division chief and medical laboratory director of Molecular Diagnostics since 2011. His research interests focus on molecular oncology, identifying genetic alterations that drive the development and behavior of cancers, and translate those findings into diagnostic applications that enable the proper selection of targeted therapies in precision oncology. Some of his more notable accomplishments include leading pathology efforts in multidisciplinary projects such as the discovery of oncogenic EGFR mutations as targetable alterations in lung cancer, detection of MYD88 alterations in Waldenstrom's macroglobulinemia, and the leadership of the Profile pan-cancer genomic sequencing program at the Dana-Farber/Brigham Cancer Center. He has led the development of dozens of clinical molecular diagnostics assays, authored or co-authored over 160 scientific papers, co-chaired an international working group from three professional societies that established, and then updated, evidence-based practice guidelines for molecular pathology of lung cancer, trained scores of residents and fellows, and has served in a leadership capacity in multiple professional societies within pathology.